Table 2.
Meta-analyses on lamivudine prophylaxis for HBV reactivation during chemotherapy in HBsAg-positive patients.
| Meta-analyses |
Studies included |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study design | RCT | Lmv E/N | No E/N | RR [95%CI] | Prospective | Lmv E/N | No E/N | RR [95%CI] | Retrospective | Lmv E/N | No E/N | RR [95%CI] |
| Kohrt et al. [2006] | Lau et al. [2003] | 0/15 | 8/15 | Idilman et al. [2004] | 0/8 | 5/10 | ||||||
| Dai et al. [2004b] | 1/6 | 0 | ||||||||||
| Dai et al. [2004c] | 0/11 | 5/9 | ||||||||||
| Yeo et al. [2004b] | 2/31 | 19/61 | ||||||||||
| Yeo et al. [2005] | 0/16 | 6/21 | ||||||||||
| el-Sayed et al. [2004] | 0/10 | 0 | ||||||||||
| Hui et al. [2005] | 11/46 | 0 | ||||||||||
| Rossi et al. [2001] | 1/20 | 0 | ||||||||||
| Vassiliadis et al. [2005] | 0/10 | 0 | ||||||||||
| Loomba et al. [2008] | Lau et al. [2003] | 0/15 | 8/15 | 0.00 [0.00–0.39] | Jia and Lin [2004] | 1/8 | 7/8 | 0.14 [0.01–0.67] | Lim et al. [2002] | 0/16 | 7/19 | 0.00 [0.00–0.56] |
| Jang et al. [2006] | 1/36 | 15/37 | 0.07 [0.01–0.35] | Idilman et al. [2004] | 0/8 | 5/10 | 0.00 [0.00–0.79] | Leaw et al. [2004] | 0/11 | 17/53 | 0.00 [0.00–0.86] | |
| Hsu et al. [2006] | 3/26 | 14/25 | 0.21 [0.04–0.59] | Shibolet et al. [2002] | 0/9 | 2/5 | 0.00 [0.00–1.31] | Nagamatsu et al. [2004] | 0/8 | 6/9 | 0.00 [0.00–0.66] | |
| Dai et al. [2004c] | 0/11 | 5/9 | 0.00 [0.00–0.61] | Lee et al. [2003] | 1/11 | 17/20 | 0.11 [0.01–0.46] | |||||
| Yeo et al. [2004a] | 3/65 | 47/193 | 0.19 [0.04–0.52] | |||||||||
| Yeo et al. [2005] | 0/16 | 6/21 | 0.00 [0.00–0.75] | |||||||||
| Martyak et al. [2008] | Lau et al. [2003] | 0/15 | 8/15 | Idilman et al. [2004] | 0/8 | 5/10 | Lim et al. [2002] | 0/16 | 7/19 | |||
| Jang et al. [2006] | 1/36 | 15/37 | Dai et al. [2004c] | 0/11 | 5/9 | Lee et al. [2003] | 1/11 | 17/20 | ||||
| Yeo et al. [2004b] | 2/31 | 19/61 | Sugimoto et al. [2004] | 0/5 | 6/6 | |||||||
| Yeo et al. [2004a] | 3/65 | 47/193 | ||||||||||
| Yeo et al. [2005] | 0/16 | 6/21 | ||||||||||
| Ziakas et al. [2009]* | Lau et al. [2003] | 0/15 | 8/15 | 0.06 [0.00–0.94] | Idilman et al. [2004] | 0/4 | 2/3 | 0.16 [0.01–2.47] | Leaw et al. [2004] | 0/11 | 17/53 | 0.13 [0.01–1.99] |
| Hsu et al. [2008] | 3/26 | 14/25 | 0.21 [0.07–0.63] | Shibolet et al. [2002] | 0/7 | 2/4 | 0.13 [0.01–2.10] | Lee et al. [2003] | 1/11 | 17/20 | 0.11 [0.02–0.70] | |
| Li et al. [2006] | 7/40 | 60/116 | 0.34 [0.17–0.68] | |||||||||
| Persico et al. [2002] | 0/3 | 12/18 | 0.19 [0.01–2.59] | |||||||||
| Tsutsumi et al. [2009] | 0/10 | 4/15 | 0.16 [0.01–2.71] | |||||||||
RCT, randomized controlled trial; Lmv, lamivudine prophylaxis; No, no prophylaxis; E/N, events/total number; RR, relative risk; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen.
*
Lymphoma patients.